Board of Directors

David Chiswell, Ph.D. – Chairman

Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP

Read More

Anne Klibanski, M.D.

President and CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Read More

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Read More

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics

Read More

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Read More

Davey S. Scoon

Former CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors

Read More

Ron Cooper

President and Chief Executive Officer

Read More